Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

Published:2014-12-31 Issue:5 Volume:4 Page:673-681
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Hainsworth John D.¹²,Thompson Dana S.¹²,Bismayer John A.¹³,Gian Victor G.¹²,Merritt William M.¹⁴,Whorf Robert C.¹⁵,Finney Lindsey H.¹,Dudley B. Stephens¹²

Affiliation:

1. Sarah Cannon Research Institute Nashville Tennessee

2. Tennessee Oncology PLLC Nashville Tennessee

3. Oncology Hematology Care Cincinnati Ohio

4. South Carolina Oncology Associates Columbia South Carolina

5. Florida Cancer Specialists Fort Myers Florida

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.376

Reference23 articles.

1. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

2. A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

3. Molecular and biological properties of vascular endothelial growth factor

4. The prognostic significance of angiogenesis in epithelial ovarian carcinoma;Alvarez A. A.;Clin. Cancer Res.,1999

5. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities;Current Oncology;2024-07-01

2. Synergistic Action of Benzyl Isothiocyanate and Sorafenib in a Nanoparticle Delivery System for Enhanced Triple-Negative Breast Cancer Treatment;Cancers;2024-04-26

3. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies;Frontiers in Oncology;2023-06-28

4. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18

5. Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine;Frontiers in Pharmacology;2023-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3